BTK and autoimmune thrombocytopenic purpura: Building on this approach, Rilzabrutinib, a new oral, reversible Bruton Tyrosine Kinase inhibitor, has recently been FDA-approved for adult ITP patients who did not show a sufficient response to previous therapies.